Europe Self-injection Devices Market Outlook

the europe market scenario for self-injection devices is reflective of a robust environment with increasing demand among the population. this is mainly attributed to rising awareness regarding the benefits of self-injection devices through the proactive efforts of pharmaceutical companies and also advancements made in the device technology. as per a report by delveinsight, europe is expected to be the second largest self-injection devices market in 2018-2032. the major factors driving the growth in europe self-injection devices market are favorable government regulations, growing geriatric population, increasing prevalence of chronic diseases, rise in awareness about self-injection devices, technological advancement in self-injection devices such as auto-injectors, and availability of specialty drugs and biologics. firmly established healthcare infrastructure in the european countries is expected to significantly contribute to the growth of the self-injection device market. as per a report by the organization for economic co-operation and development (oecd), average healthcare expenditure in these countries is about 5% higher than other nations. moreover, the healthcare reimbursement policy is expected to support reimbursement for self-injection devices among eligible patients. this is expected to further foster the growth of the self-injection devices market. a factor straining the growth of the self-injection devices market is the high price of the device. according to delveinsight, autoinjectors have a relatively high cost due to their sophisticated design and drug complexity. this high cost is expected to create affordability issues for the patient population and thus discourage the uptake of such devices. however, the entry of new players and the development of innovative devices is expected to lead to increased availability of self-injection devices at a more affordable price. furthermore, increasing cost consciousness among healthcare organizations is inducing drug manufacturers to assemble and customize self-injection devices with service and management programs to control health costs which are expected to drive the market in the future.